AstraZeneca says vaccine has shown encouraging immune response

AstraZeneca says vaccine has shown  encouraging  immune response
LONDON, UNITED KINGDOM -- British pharma giant AstraZeneca said on Monday trials of its coronavirus vaccine pioneered with Oxford University had shown "encouraging" responses among elderly, as well as younger participants.

The potential vaccine, one of 10 around the world in the most advanced phase III of trials, showed "strong immune responses" in all adult groups during the previous stage, according to an update from Oxford.

An AstraZeneca spokesman said the initial results "further build the body of evidence for the safety and immunogenicity" of its experimental vaccine.

"It is encouraging to see immunogenicity responses were similar between older and younger adults, the spokesman added.

The positive news emerged in data on the safety and immune responses of participants in the phase II stage of the trial Oxford has submitted for peer review in a medical journal.

They include results for U.K. volunteers aged 56-69 and over 70, with formal publication of the data expected "in the coming weeks."

"Our ongoing trials will provide further data, but this marks a key milestone and reassures us that the vaccine is safe for use and induces strong immune responses in both parts of the immune system in all adult groups," the university said.

Oxford and AstraZeneca have been trialing their potential vaccine for months in various countries around the world.

It was suspended worldwide on September 6 after a participant s illness, but resumed shortly thereafter in Britain, and in the following weeks in South Africa, Brazil and Japan.

Authorities determined the illness was not apparently linked to the vaccine, with the U.S. Food and Drug Administration also authorising the restart in the United States at the weekend.

The AstraZeneca/Oxford vaccine is one of the most promising and advanced in the world to combat the global pandemic, which has now claimed the lives of 1.1 million people.

Many countries are counting on using it to inoculate their populations.

The drugmaker pre-sold hundreds of millions of doses on several continents, and signed partnership deals with other producers to ensure the doses could be made locally.

U.K. Health Secretary Matt Hancock further fuelled optimism Monday, noting in an interview that once approved the "bulk" of the vaccine s rollout could occur in Britain before next summer.
Read more on CTVnews
News Topics :
Similar Articles :
BENGALURU/LONDON Reuters The United States has secured almost a third of AstraZeneca’s one billion possible COVID 19 vaccine doses by pledging up to $1.2 billion, as the world’s biggest powers...
One of the most promising experimental vaccines for COVID 19,  currently being tested by Oxford University and commercial partner AstraZeneca, is effective in both older adults and young people — which is heartening...
Reuters AstraZeneca expects to be able to deliver a billion doses of a possible COVID 19 vaccine this year and next if tests are successful, adding on Thursday it should...
Canada U.K. Australia Brazil España France Ελλάδα Greece India Italia 日本 Japan 한국 Korea Quebec U.S. Edition LONDON Reuters AstraZeneca and Oxford University’s potential COVID 19 vaccine produced a strong...
A phase 2 trial of an Ad5 vectored COVID 19 vaccine candidate, conducted in China, has found that the vaccine is safe and induces an immune response, according to new research...